Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiodarone formulation in stable congestive heart failure
NCT00739193Phase 2Withdrawn
- Sponsor
- Prism Pharmaceuticals
- Start
- Aug 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of amiodarone in ventricular fibrillation (VF) and ventricular tachycardia (VT) (3 arms), sponsored by Prism Pharmaceuticals. Primary endpoint: Systolic blood pressure at 15 minutes. Planned start Aug 2008; status: withdrawn.
02
Drugs
amiodarone
03
Conditions
ventricular fibrillation (VF)ventricular tachycardia (VT)
Beyond the preview
Go deeper on NCT00739193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00739193.